ClinicalTrials.gg
CompletedNCT03496168PIONEER-OLEUpdated Jan 9, 2025Results posted

Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in PIONEER

A Phase 2 interventional study of mavacamten in Hypertrophic Cardiomyopathy, sponsored by Bristol-Myers Squibb. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-09.

Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
13
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 21 studies testing MYK-461 in Cardiomyopathy, Hypertrophic — 3 open to participants now, 7 under way, 1 of them phase 3. MYK-461 · Cardiomyopathy, Hypertrophic.

Enrollment
21st of 21
13 · median 75
Started
2018
with 3 others
Phase 2
3 of 21
none open now
Registered
6th of 21
by date
Lead sponsor
10 of 21
Bristol-Myers Squibb

Among the 21 studies testing MYK-461 in Cardiomyopathy, Hypertrophic, this one is the 21st largest by enrollment, is one of 4 that started in 2018, is one of 3 in phase 2, and was the 6th registered.

Cardiomyopathy, Hypertrophic

363 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 116 are open to participants now.

Browse Cardiomyopathy, Hypertrophic studies →

Open to participants now

3 of the 21 studies testing MYK-461 in Cardiomyopathy, Hypertrophic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About MYK-461

MYK-461: first FDA approval 2022 (CAMZYOS), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 81 Cardiomyopathy, Hypertrophic studies recruiting now, 55 (68%) set no upper age limit and 8 (10%) stop at 75 or younger; 21 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing MYK-461 in Cardiomyopathy, Hypertrophic, or all of them as a file.
02

Study summary

This is a multicenter open-label study of the administration of mavacamten in participants with symptomatic obstructive HCM (oHCM) who previously participated in study MYK-461-004 (PIONEER-HCM).

03

Conditions studied

  • Hypertrophic Cardiomyopathy

Keywords

  • Symptomatic
  • Obstructive
  • Left ventricular outflow tract gradient
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Completed Study MYK-461-004. Prior participation in a non-interventional observational study is allowed.
  • Body weight > 45 kg at Screening
  • Has safety laboratory parameters (chemistry and hematology) within normal limits

Key Exclusion Criteria:

  • Has > > 500 ms or any other abnormality considered by the investigator to pose a risk to subject safety (eg, second degree atrioventricular block type II)
  • Since enrollment into Study MYK-461-004, has developed obstructive coronary artery disease (> 70% stenosis in one or more arteries) or known moderate or severe aortic valve stenosis
  • Since enrollment into Study MYK-461-004, has developed any acute or serious comorbid condition (eg, major infection or hematologic, renal, metabolic, gastrointestinal, or endocrine dysfunction) that, in the opinion of the investigator or medical monitor, would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion
  • Since enrollment into Study MYK-461-004 has developed malignant disease
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    mavacamten (MYK-461)

    Drug: mavacamten

Interventions

  • mavacamten capsules

    Also known as: MYK-461

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events and Treatment Emergent Serious Adverse Events

    AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product; it does not necessarily have to have a causal relationship with this treatment. An SAE is defined as any untoward medical occurrence at any dose that: * Results in death * Is immediately life-threatening (places the participant at immediate risk of death from the event as it occurred) * Requires inpatient hospitalization or prolongation of existing hospitalization * Results in persistent or significant disability or incapacity or substantial disruption of the ability to conduct normal life functions * Results in a congenital abnormality or birth defect * Is an important medical event that may not result in death, be life- threatening, or require hospitalization, but may be considered an SAE when, based upon appropriate medical judgment, it may require medical or surgical intervention to prevent any of the outcomes listed above.

    Time frame: From first dose to end of treatment + 56 days (Approximately an average of 240 Weeks)

  2. Number of Participants Who Had Cardiovascular Death

    Number of participants who had died due to cardiovascular reasons.

    Time frame: From first dose to end of study, (approximately 260 weeks)

  3. Number of Participants Who Experienced Sudden Death

    Number of participants who experienced sudden death

    Time frame: From first dose to end of study, (approximately 260 weeks)

  4. Number of Participants Who Were Hospitalized for Cardiovascular Reasons.

    Number of participants who were hospitalized for cardiovascular reasons.

    Time frame: From first dose to end of study, (approximately 260 weeks)

  5. Number of Participants With Heart Failure Due to Systolic Dysfunction, Defined as Asymptomatic LVEF < 50%

    Number of participants with heart failure due to systolic dysfunction, defined as asymptomatic LVEF \< 50%

    Time frame: From first dose to end of study, (approximately 260 weeks)

  6. Number of Participants With LVEF < 50% as Measured by Echocardiography.

    Number of participants with LVEF \< 50% as measured by echocardiography.

    Time frame: From first dose to end of study, (approximately 260 weeks)

  7. Number of Participants Who Were Experienced Myocardial Infarction

    Number of participants who experienced myocardial infarction.

    Time frame: From first dose to end of study, (approximately 260 weeks)

  8. Number of Participants With Ventricular Arrhythmias.

    Types of Ventricular Arrhythmias measured in this endpoint will be: Ventricular Tachycardia Ventricular Fibrilation Ventricular Flutter

    Time frame: From first dose to end of study, (approximately 260 weeks)

  9. Number of Participants Who Experienced Syncope

    Number of participants who experienced syncope. Syncope will be defined as participants who experienced dizziness or orthostatic hypotension.

    Time frame: From first dose to end of study, (approximately 260 weeks)

  10. Number of Participants Who Experienced Seizures

    Number of participants who were experienced seizures.

    Time frame: From first dose to end of study, (approximately 260 weeks)

  11. Number of Participants Who Were Experienced Strokes

    Number of participants who were experienced strokes.

    Time frame: From first dose to end of study, (approximately 260 weeks)

  12. Number of Participants With a Change in QT and QTcF Intervals.

    Number of participants with a change in QTcF intervals. QTcF: An electrocardiographic finding in which the QT interval corrected for heart rate using Fridericia's formula. QTc = QT/∛(RR/1000) RR = Respiration rate QT Interval: Ventricular depolarization plus ventricular repolarization Normal Range: 400 to 460 msec

    Time frame: From first dose to end of study, (approximately 260 weeks)

  13. Post-exercise Left Ventricular Outflow Tract (LVOT) Gradient Over Time

    Number of participants with changes of Post-exercise left ventricular outflow tract (LVOT) gradient over time

    Time frame: At Baseline, Week 4, Week 48, Week 72, Week 156, Week 204 and Week 252

  14. Resting Left Ventricular Outflow Tract (LVOT) Gradient Over Time

    Resting left ventricular outflow tract (LVOT) gradient over time

    Time frame: At Baseline, Week 4, Week 48, Week 72, Week 156, Week 204 and Week 252

  15. Post Valsalva Left Ventricular Outflow Tract (LVOT) Gradient Over Time

    Post Valsalva left ventricular outflow tract (LVOT) gradient over time

    Time frame: At Baseline, Week 4, Week 48, Week 72, Week 156, Week 204 and Week 252

  16. Participants With >= 1 NYHA Function Class Improvement

    Participants with \>= 1 NYHA function class improvement. The NYHA Functional Classification of heart failure assigns participants to 1 of 4 categories based on the participant's symptoms. Class 1: No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea (shortness of breath). Class 2: Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea (shortness of breath). Class 3: Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, or dyspnea. Class 4: Unable to carry on any physical activity without discomfort. Symptoms of heart failure at rest. If any physical activity is undertaken, discomfort increases.

    Time frame: At Baseline, Week 4, Week 8, Week 24, Week 48, Week 72, Week 96, Week 120, Week 144, Week 156, Week 180, Week 204, Week 228 and Week 252

  17. Mean Change From Baseline in the Overall KCCQ PRO Score.

    The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a self-administered 23-item questionnaire questionnaire that measure the participant's perception of their health status, including their heart failure (HF) symptoms, impact on physical and social function and how their HF impacts the quality of life. KCCQ quantifies 7 domains: physical limitations (6 items), symptom stability (1 item), symptom frequency (4 items), symptom burden (3 items), self-efficacy (2 items), quality of life (3 items) and social limitations (4 items). Scores were generated for each domain and scaled from 0 to 100, with 0 denoting the worst and 100 the best possible status. Overall KCCQ Pro score is the average of all the domains, symptom frequency and symptom burden scores, and transformed to a single score which ranged from 0 (worst) to 100 (the best possible status), where the higher score reflected better health status.

    Time frame: At Baseline, Week 4, Week 8, Week 24, Week 48, Week 72, Week 96, Week 120, Week 144, Week 156, Week 180, Week 204, Week 228 and Week 252

  18. Mean Change From Baseline in Serum NT-proBNP.

    Mean change from baseline in Serum N-terminal pro B-type natriuretic peptide levels.

    Time frame: At Baseline, Week 4, Week 8, Week 24, Week 48, Week 72, Week 96, Week 120, Week 144, Week 156, Week 180, Week 204, Week 228 and Week 252

  19. Number of Participants Who Received Septal Reduction Therapy

    Number of participants who received septal reduction therapy

    Time frame: 252 weeks

  20. Plasma Concentration of Mavacamen Overtime

    Plasma concentration of Mavacamen overtime

    Time frame: At Baseline, Week 4, Week 8, Week 24, Week 48, Week 72, Week 96, Week 120, Week 144, Week 156, Week 180, Week 204, Week 228 and Week 252

07

Results

Posted Jan 9, 2025

Participant flow

Participant flow — Overall Study
MilestoneMavacamtem
Started13
Completed11
Not completed2
Withdrew: Other reasons1
Withdrew: Adverse event1

Outcome measures

PrimaryNumber of Participants With Treatment Emergent Adverse Events and Treatment Emergent Serious Adverse Events

AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product; it does not necessarily have to have a causal relationship with this treatment. An SAE is defined as any untoward medical occurrence at any dose that: * Results in death * Is immediately life-threatening (places the participant at immediate risk of death from the event as it occurred) * Requires inpatient hospitalization or prolongation of existing hospitalization * Results in persistent or significant disability or incapacity or substantial disruption of the ability to conduct normal life functions * Results in a congenital abnormality or birth defect * Is an important medical event that may not result in death, be life- threatening, or require hospitalization, but may be considered an SAE when, based upon appropriate medical judgment, it may require medical or surgical intervention to prevent any of the outcomes listed above.

Time frame:
From first dose to end of treatment + 56 days (Approximately an average of 240 Weeks)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events and Treatment Emergent Serious Adverse Events
ParticipantsMavacamtem
TEAEs13
TESAEs5
PrimaryNumber of Participants Who Had Cardiovascular Death

Number of participants who had died due to cardiovascular reasons.

Time frame:
From first dose to end of study, (approximately 260 weeks)
Reported as:
Count of participants · Participants
Number of Participants Who Had Cardiovascular Death
ParticipantsMavacamtem
Number of Participants Who Had Cardiovascular Death0
PrimaryNumber of Participants Who Experienced Sudden Death

Number of participants who experienced sudden death

Time frame:
From first dose to end of study, (approximately 260 weeks)
Reported as:
Count of participants · Participants
Number of Participants Who Experienced Sudden Death
ParticipantsMavacamtem
Number of Participants Who Experienced Sudden Death0
PrimaryNumber of Participants Who Were Hospitalized for Cardiovascular Reasons.

Number of participants who were hospitalized for cardiovascular reasons.

Time frame:
From first dose to end of study, (approximately 260 weeks)
Reported as:
Count of participants · Participants
Number of Participants Who Were Hospitalized for Cardiovascular Reasons.
ParticipantsMavacamtem
Number of Participants Who Were Hospitalized for Cardiovascular Reasons.1
PrimaryNumber of Participants With Heart Failure Due to Systolic Dysfunction, Defined as Asymptomatic LVEF < 50%

Number of participants with heart failure due to systolic dysfunction, defined as asymptomatic LVEF \< 50%

Time frame:
From first dose to end of study, (approximately 260 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Heart Failure Due to Systolic Dysfunction, Defined as Asymptomatic LVEF < 50%
ParticipantsMavacamtem
Number of Participants With Heart Failure Due to Systolic Dysfunction, Defined as Asymptomatic LVEF < 50%0
PrimaryNumber of Participants With LVEF < 50% as Measured by Echocardiography.

Number of participants with LVEF \< 50% as measured by echocardiography.

Time frame:
From first dose to end of study, (approximately 260 weeks)
Reported as:
Count of participants · Participants
Number of Participants With LVEF < 50% as Measured by Echocardiography.
ParticipantsMavacamtem
Number of Participants With LVEF < 50% as Measured by Echocardiography.2
PrimaryNumber of Participants Who Were Experienced Myocardial Infarction

Number of participants who experienced myocardial infarction.

Time frame:
From first dose to end of study, (approximately 260 weeks)
Reported as:
Count of participants · Participants
Number of Participants Who Were Experienced Myocardial Infarction
ParticipantsMavacamtem
Number of Participants Who Were Experienced Myocardial Infarction0
PrimaryNumber of Participants With Ventricular Arrhythmias.

Types of Ventricular Arrhythmias measured in this endpoint will be: Ventricular Tachycardia Ventricular Fibrilation Ventricular Flutter

Time frame:
From first dose to end of study, (approximately 260 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Ventricular Arrhythmias.
ParticipantsMavacamtem
Ventricular Tachycardia1
Ventricular Fibrilation0
Ventricular Flutter0
Torsades De Pointe0
PrimaryNumber of Participants Who Experienced Syncope

Number of participants who experienced syncope. Syncope will be defined as participants who experienced dizziness or orthostatic hypotension.

Time frame:
From first dose to end of study, (approximately 260 weeks)
Reported as:
Count of participants · Participants
Number of Participants Who Experienced Syncope
ParticipantsMavacamtem
Dizziness2
Orthostatic Hypotension1
PrimaryNumber of Participants Who Experienced Seizures

Number of participants who were experienced seizures.

Time frame:
From first dose to end of study, (approximately 260 weeks)
Reported as:
Count of participants · Participants
Number of Participants Who Experienced Seizures
ParticipantsMavacamtem
Number of Participants Who Experienced Seizures0
PrimaryNumber of Participants Who Were Experienced Strokes

Number of participants who were experienced strokes.

Time frame:
From first dose to end of study, (approximately 260 weeks)
Reported as:
Count of participants · Participants
Number of Participants Who Were Experienced Strokes
ParticipantsMavacamtem
Number of Participants Who Were Experienced Strokes0
PrimaryNumber of Participants With a Change in QT and QTcF Intervals.

Number of participants with a change in QTcF intervals. QTcF: An electrocardiographic finding in which the QT interval corrected for heart rate using Fridericia's formula. QTc = QT/∛(RR/1000) RR = Respiration rate QT Interval: Ventricular depolarization plus ventricular repolarization Normal Range: 400 to 460 msec

Time frame:
From first dose to end of study, (approximately 260 weeks)
Reported as:
Count of participants · Participants
Number of Participants With a Change in QT and QTcF Intervals.
ParticipantsMavacamtem
Post Baseline QTcF > 450msec7
Post Baseline QTcF > 480msec1
Post Baseline QTcF > 500msec1
Change from Baseline QTcF > 30 msec2
Change from Baseline QTcF > 60 msec1
PrimaryPost-exercise Left Ventricular Outflow Tract (LVOT) Gradient Over Time

Number of participants with changes of Post-exercise left ventricular outflow tract (LVOT) gradient over time

Time frame:
At Baseline, Week 4, Week 48, Week 72, Week 156, Week 204 and Week 252
Reported as:
Count of participants · Participants
Post-exercise Left Ventricular Outflow Tract (LVOT) Gradient Over Time
ParticipantsMavacamtem
Baseline — < 30 mmHg0
Baseline — >= 30 mmHg to < 50 mmHg0
Baseline — >= 50 mmHg13
Week 4 — < 30 mmHg0
Week 4 — >= 30 mmHg to < 50 mmHg3
Week 4 — >= 50 mmHg10
Week 48 — < 30 mmHg6
Week 48 — >= 30 mmHg to < 50 mmHg3
Week 48 — >= 50 mmHg2
Week 72 — < 30 mmHg8
Week 72 — >= 30 mmHg to < 50 mmHg0
Week 72 — >= 50 mmHg3
Week 156 — < 30 mmHg10
Week 156 — >= 30 mmHg to < 50 mmHg0
Week 156 — >= 50 mmHg2
Week 204 — < 30 mmHg9
Week 204 — >= 30 mmHg to < 50 mmHg1
Week 204 — >= 50 mmHg2
Week 252 — < 30 mmHg9
Week 252 — >= 30 mmHg to < 50 mmHg0
Week 252 — >= 50 mmHg2
PrimaryResting Left Ventricular Outflow Tract (LVOT) Gradient Over Time

Resting left ventricular outflow tract (LVOT) gradient over time

Time frame:
At Baseline, Week 4, Week 48, Week 72, Week 156, Week 204 and Week 252
Reported as:
Count of participants · Participants
Resting Left Ventricular Outflow Tract (LVOT) Gradient Over Time
ParticipantsMavacamtem
Baseline — < 30 mmHg3
Baseline — >= 30 mmHg to < 50 mmHg2
Baseline — >= 50 mmHg8
Week 4 — < 30 mmHg8
Week 4 — >= 30 mmHg to < 50 mmHg0
Week 4 — >= 50 mmHg5
Week 48 — < 30 mmHg11
Week 48 — >= 30 mmHg to < 50 mmHg1
Week 48 — >= 50 mmHg0
Week 72 — < 30 mmHg11
Week 72 — >= 30 mmHg to < 50 mmHg0
Week 72 — >= 50 mmHg0
Week 156 — < 30 mmHg11
Week 156 — >= 30 mmHg to < 50 mmHg1
Week 156 — >= 50 mmHg0
Week 204 — < 30 mmHg10
Week 204 — >= 30 mmHg to < 50 mmHg1
Week 204 — >= 50 mmHg1
Week 252 — < 30 mmHg11
Week 252 — >= 30 mmHg to < 50 mmHg0
Week 252 — >= 50 mmHg0
PrimaryPost Valsalva Left Ventricular Outflow Tract (LVOT) Gradient Over Time

Post Valsalva left ventricular outflow tract (LVOT) gradient over time

Time frame:
At Baseline, Week 4, Week 48, Week 72, Week 156, Week 204 and Week 252
Reported as:
Count of participants · Participants
Post Valsalva Left Ventricular Outflow Tract (LVOT) Gradient Over Time
ParticipantsMavacamtem
Baseline — < 30 mmHg0
Baseline — >= 30 mmHg to < 50 mmHg1
Baseline — >= 50 mmHg11
Week 4 — < 30 mmHg3
Week 4 — >= 30 mmHg to < 50 mmHg2
Week 4 — >= 50 mmHg8
Week 48 — < 30 mmHg9
Week 48 — >= 30 mmHg to < 50 mmHg1
Week 48 — >= 50 mmHg2
Week 72 — < 30 mmHg9
Week 72 — >= 30 mmHg to < 50 mmHg1
Week 72 — >= 50 mmHg1
Week 156 — < 30 mmHg10
Week 156 — >= 30 mmHg to < 50 mmHg1
Week 156 — >= 50 mmHg1
Week 204 — < 30 mmHg9
Week 204 — >= 30 mmHg to < 50 mmHg0
Week 204 — >= 50 mmHg3
Week 252 — < 30 mmHg10
Week 252 — >= 30 mmHg to < 50 mmHg0
Week 252 — >= 50 mmHg1
PrimaryParticipants With >= 1 NYHA Function Class Improvement

Participants with \>= 1 NYHA function class improvement. The NYHA Functional Classification of heart failure assigns participants to 1 of 4 categories based on the participant's symptoms. Class 1: No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea (shortness of breath). Class 2: Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea (shortness of breath). Class 3: Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, or dyspnea. Class 4: Unable to carry on any physical activity without discomfort. Symptoms of heart failure at rest. If any physical activity is undertaken, discomfort increases.

Time frame:
At Baseline, Week 4, Week 8, Week 24, Week 48, Week 72, Week 96, Week 120, Week 144, Week 156, Week 180, Week 204, Week 228 and Week 252
Reported as:
Number · Percentage of Participants
Participants With >= 1 NYHA Function Class Improvement
Percentage of ParticipantsMavacamtem
Change from baseline at week 415.4 (1.92 to 45.45)
Change from baseline at week 846.2 (19.22 to 74.87)
Change from baseline at week 2476.9 (46.19 to 94.96)
Change from baseline at week 4875.0 (42.81 to 94.51)
Change from baseline at week 7290.9 (58.72 to 99.77)
Change from baseline at week 9683.3 (51.59 to 97.91)
Change from baseline at week 12091.7 (61.52 to 99.79)
Change from baseline at week 14491.7 (61.52 to 99.79)
Change from baseline at week 15691.7 (61.52 to 99.79)
Change from baseline at week 18083.3 (51.59 to 97.91)
Change from baseline at week 20483.3 (51.59 to 97.91)
Change from baseline at week 22883.3 (51.59 to 97.91)
Change from baseline at week 25290.9 (58.72 to 99.77)
PrimaryMean Change From Baseline in the Overall KCCQ PRO Score.

The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a self-administered 23-item questionnaire questionnaire that measure the participant's perception of their health status, including their heart failure (HF) symptoms, impact on physical and social function and how their HF impacts the quality of life. KCCQ quantifies 7 domains: physical limitations (6 items), symptom stability (1 item), symptom frequency (4 items), symptom burden (3 items), self-efficacy (2 items), quality of life (3 items) and social limitations (4 items). Scores were generated for each domain and scaled from 0 to 100, with 0 denoting the worst and 100 the best possible status. Overall KCCQ Pro score is the average of all the domains, symptom frequency and symptom burden scores, and transformed to a single score which ranged from 0 (worst) to 100 (the best possible status), where the higher score reflected better health status.

Time frame:
At Baseline, Week 4, Week 8, Week 24, Week 48, Week 72, Week 96, Week 120, Week 144, Week 156, Week 180, Week 204, Week 228 and Week 252
Reported as:
Mean · Scores on a Scale
Mean Change From Baseline in the Overall KCCQ PRO Score.
Scores on a ScaleMavacamtem
Change from baseline at week 45.809 ± 8.7200
Change from baseline at week 812.304 ± 15.7392
Change from baseline at week 2416.931 ± 18.4502
Change from baseline at week 4816.345 ± 18.2986
Change from baseline at week 7218.600 ± 16.7875
Change from baseline at week 9616.162 ± 18.2376
Change from baseline at week 12018.142 ± 15.9249
Change from baseline at week 14417.860 ± 15.5829
Change from baseline at week 15618.750 ± 15.5701
Change from baseline at week 18016.674 ± 15.6328
Change from baseline at week 20419.661 ± 15.9783
Change from baseline at week 22891.122 ± 10.6882
Change from baseline at week 25289.489 ± 12.7977
PrimaryMean Change From Baseline in Serum NT-proBNP.

Mean change from baseline in Serum N-terminal pro B-type natriuretic peptide levels.

Time frame:
At Baseline, Week 4, Week 8, Week 24, Week 48, Week 72, Week 96, Week 120, Week 144, Week 156, Week 180, Week 204, Week 228 and Week 252
Reported as:
Mean · ng/L
Mean Change From Baseline in Serum NT-proBNP.
ng/LMavacamtem
Change from baseline at week 4-1017.4 ± 1540.78
Change from baseline at week 8-1440.6 ± 2063.89
Change from baseline at week 24-1512.8 ± 2242.40
Change from baseline at week 48-1579.2 ± 2328.81
Change from baseline at week 72-1708.4 ± 2448.93
Change from baseline at week 96-1579.1 ± 2339.95
Change from baseline at week 120-1692.7 ± 2426.02
Change from baseline at week 144-1507.8 ± 2407.34
Change from baseline at week 156-1673.5 ± 2460.82
Change from baseline at week 180-1433.6 ± 2347.72
Change from baseline at week 204-1568.7 ± 2400.63
Change from baseline at week 228-1325.5 ± 2368.77
Change from baseline at week 252-1681.5 ± 2409.67
PrimaryNumber of Participants Who Received Septal Reduction Therapy

Number of participants who received septal reduction therapy

Time frame:
252 weeks
Reported as:
Count of participants · Participants
Number of Participants Who Received Septal Reduction Therapy
ParticipantsMavacamtem
Number of Participants Who Received Septal Reduction Therapy0
PrimaryPlasma Concentration of Mavacamen Overtime

Plasma concentration of Mavacamen overtime

Time frame:
At Baseline, Week 4, Week 8, Week 24, Week 48, Week 72, Week 96, Week 120, Week 144, Week 156, Week 180, Week 204, Week 228 and Week 252
Reported as:
Geometric mean · ng/mL
Plasma Concentration of Mavacamen Overtime
ng/mLMavacamtem
Week 4166.51 ± 32.1
Week 8334.65 ± 21.5
Week 24396.18 ± 31.7
Week 48400.15 ± 35.1
Week 72407.27 ± 24.4
Week 96422.82 ± 29.3
Week 120399.17 ± 33.2
Week 144410.23 ± 42.8
Week 156400.02 ± 44.1
Week 180265.04 ± 57.9
Week 204376.25 ± 69.5
Week 228355.29 ± 72.3
Week 252334.57 ± 52.1

Adverse events

Collected over Adverse Events and Serious Adverse Events: (From first dose to last dose + 56 days): Approximately 240 Weeks All-Cause mortality (From randomization to end of study): Approximately 260 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Mavacamten0/13 (0%)5/13 (38.5%)13/13 (100%)
Most frequent serious events
Most frequent serious events
EventMavacamten
Mitral valve incompetenceCardiac disorders1/13
Cholecystitis acuteHepatobiliary disorders1/13
Lumbar vertebral fractureInjury, poisoning and procedural complications1/13
Spinal compression fractureInjury, poisoning and procedural complications1/13
Subdural haematomaInjury, poisoning and procedural complications1/13
CholangiocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/13
Lumbar radiculopathyNervous system disorders1/13
Aortic stenosisVascular disorders1/13
Most frequent other events
Showing 10 of 102
Most frequent other events
EventMavacamten
FatigueGeneral disorders5/13
NasopharyngitisInfections and infestations5/13
Upper respiratory tract infectionInfections and infestations5/13
ArthralgiaMusculoskeletal and connective tissue disorders5/13
HypertensionVascular disorders4/13
Dizziness posturalNervous system disorders3/13
DyspnoeaRespiratory, thoracic and mediastinal disorders3/13
DiarrhoeaGastrointestinal disorders2/13
FallInjury, poisoning and procedural complications2/13
Drug level increasedInvestigations2/13

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Mavacamtem
Mean57.8 ± 13.3
Sex: Female, Male
Sex: Female, Male(Participants)Mavacamtem
Female4
Male9
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Mavacamtem
Hispanic or Latino0
Not Hispanic or Latino13
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Mavacamtem
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American1
White12
More than one race0
Unknown or Not Reported0
08

Study locations

4 sites
  • Local Institution - 0003
    Scottsdale, Arizona 85259, United States
  • Local Institution - 0001
    New Haven, Connecticut 06520-8017, United States
  • Local Institution - 0004
    Durham, North Carolina 27710, United States
  • Local Institution - 0002
    Portland, Oregon 97239, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2018 to primary completion in Nov 2023, 66 months.

Results were first posted in Jan 2025, 1 year 2 months after primary completion.

Of 20 phase 2 interventional studies under Cardiomyopathy, Hypertrophic, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 43. This study's 66 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 5, 2018
First posted
Apr 12, 2018
StartActual
Apr 26, 2018
Primary completionActual
Nov 9, 2023
CompletionActual
Nov 9, 2023
Results first posted
Jan 9, 2025
Last update
Jan 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03496168
Responsible party
Sponsor
First posted
Apr 12, 2018
Start date
Apr 26, 2018
Primary completion
Nov 9, 2023
Completion
Nov 9, 2023
Results posted
Jan 9, 2025
Last update
Jan 9, 2025

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MYK-461

Start the discussion